OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time
April 29 2021 - 7:30AM
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced
today that the Company will provide a business update and report
its first quarter 2021 financial results before the open of the
U.S. financial markets on Thursday, May 13, 2021. OpGen’s
management team will host a live conference call and audio webcast
at 8:30 a.m. Eastern Time to discuss the Company’s financial
results and provide an update on business activities.
Conference Call Details |
U.S. Dial-in Number:International Dial-in Number:Webcast:Conference
ID: |
+1 (877) 705
6003+1 (201) 493
6725http://public.viavid.com/index.php?id=14474913719409 |
|
|
Replay Details |
U.S. Dial-in Number:International Dial-in Number:Replay PIN: |
+1 (844) 512 2921+1 (412) 317 667113719409 |
Following the conclusion of the conference call,
a replay will be available through May 27, 2021. The live,
listen-only webcast of the conference call may also be accessed by
visiting the Investors section of the Company’s website at
www.opgen.com. A replay of the webcast will be available following
the conclusion of the call and will be archived on the Company’s
website under Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we
are developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
OpGen:Oliver SchachtPresident
and CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PRmatt@fischtankpr.com
OpGen Investor Contact:Megan
Paul Edison Group mpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024